CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.
about
A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in UgandaPrevention of vertical transmission of HIV-1 in resource-limited settingsAntiretroviral treatment regardless of CD4 count: the universal answer to a contextual questionNew pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and fluWHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothersMaternal CD4+ cell count decline after interruption of antiretroviral prophylaxis for the prevention of mother-to-child transmission of HIVStanding genetic variation and the evolution of drug resistance in HIVCD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South AfricaA randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adultsImproved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170When to start antiretroviral therapy in resource-limited settings: a human rights analysis.Immunologic status and virologic outcomes in repeat pregnancies to HIV-positive women not on antiretroviral therapy at conception: a case for lifelong antiretroviral therapy?High correlation between Framingham equations with BMI and with lipids to estimate cardiovascular risks score at baseline in HIV-infected adults in the Temprano trial, ANRS 12136 in Côte d'Ivoire.Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression.Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parametersClinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire.CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI SubstudyThe immunological and virological consequences of planned treatment interruptions in children with HIV infection.A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy.Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committeeInferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis.Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings.Maternal HIV-1 disease progression 18-24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): The Kesho Bora randPiecewise HIV virus dynamic model with CD4(+) T cell count-guided therapy: IMaternal outcomes after HAART for the prevention of mother-to-child transmission in HIV-infected women in Brazil.HIV treatment and care in resource-constrained environments: challenges for the next decade.Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting.Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in ZimbabweAdherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling.Implementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions.The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment.Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults.
P2860
Q21559730-D8FBBE16-8F22-484D-B5D8-75A608D05B38Q22241479-3C8556BE-2493-4D03-A736-B7B2971EBA1EQ26741384-AB602E43-8BD9-42C6-8432-AD24691E479FQ27478093-F75DBE11-AC46-4894-985E-F48FA64D4FEDQ28478406-BF06C710-DD77-4D02-903C-7D16ED7BD171Q28482652-2E1653C6-D99D-4D48-92F1-E059289B5468Q28484153-471430D9-BD7C-49EC-90E0-2267221CEF3EQ28703565-9200F27A-2333-4BBA-A253-726C7DE4FC32Q28740565-1CAD366C-D437-4F16-B93C-9838030E99D2Q33377920-3C5C08F1-8C7E-47BA-8E35-691C72C72B4CQ33548096-5326C047-0B6C-4FBE-A513-96D76DDD7791Q33654652-AAE33805-7798-4FAF-BF3A-59475728BF67Q33764308-0816D4FE-B1BD-4B97-AF6C-69ABDEBF0CC4Q33786318-DAAADA76-01AE-4FD6-AFAD-6E143F0E03D0Q33875036-A3F7E211-6D3D-41F4-9D98-236FF3C86CD0Q33985842-C0612096-3361-4119-9798-A8EE6E0EA3EEQ34097961-5C79DC90-2037-4045-B191-A4B7DB7CE504Q34730855-F9A0AF62-DFE9-431F-BE8C-ADFE45E374A9Q35032305-33F59E35-67E0-4D19-9F6E-E9E0DC2B43ACQ35044399-2CA4C43C-7963-4CEE-8FF1-F209ADEA8F54Q35051199-46E5A799-E703-44DD-A90C-272546E448BCQ35124959-880E8DBF-E00D-4E75-A258-33F0791B45C3Q35129228-489FF26B-D047-45C5-88D5-ABEF8BD52856Q35147189-FE074D6C-FAB9-4704-B494-8D77D792B3C4Q35201533-214DB567-E07F-4318-B71E-C474D238A878Q35560174-D78569CC-2762-40D5-9BB9-27D339540DF4Q35562938-D35D3215-BAE2-444A-A6C4-5A4B76805276Q35621704-060D1C89-CFC2-457E-8581-2B89988791E6Q35842613-62ADC2D6-ED6C-4F10-A339-3531DE2F29B1Q36086970-3C6A2300-07C8-4A19-BDBA-9F122A34080EQ36101198-EB1ED900-DB2B-43E0-9CC4-D7E911E4CFA7Q36221392-4840C04A-F550-4254-B6A7-C83F03FA552DQ36386806-8129EFAF-6C52-4989-9B7E-D085B96FCF4BQ36398166-50CC0A93-2D97-4422-9170-27F36B44B065Q36517778-0F4ED2D6-849D-4D2E-B33C-E2E2D715A6B2Q36542643-892F9CEF-0988-4D4E-907A-1E5381E3D82CQ36627912-05C0594C-91FF-4B6B-B9BC-58133BE39E81Q36666594-FA41440E-2476-45B5-9966-9763D47D4EC8Q36692642-BB5E3523-90E7-46BC-AF1E-CD5B97F63068Q36793821-91C12936-DC2B-4ACB-B45B-3FB091444CAE
P2860
CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
CD4-guided structured antiretr ...... 69 trial): a randomised trial.
@en
CD4-guided structured antiretr ...... infected adults in west Africa
@nl
type
label
CD4-guided structured antiretr ...... 69 trial): a randomised trial.
@en
CD4-guided structured antiretr ...... infected adults in west Africa
@nl
prefLabel
CD4-guided structured antiretr ...... 69 trial): a randomised trial.
@en
CD4-guided structured antiretr ...... infected adults in west Africa
@nl
P2093
P50
P1433
P1476
CD4-guided structured antiretr ...... 69 trial): a randomised trial.
@en
P2093
Albert Minga
Amani Anzian
Constance Kanga
Delphine Sauvageot
Emmanuel Bissagnene
François Rouet
Gustave Nzunetu
Hervé Menan
Marie-Laure Chaix
Olivier Ba-Gomis
P304
P356
10.1016/S0140-6736(06)68887-9
P407
P577
2006-06-01T00:00:00Z